Scope and Claims of U.S. Patent 8,231,906: A Comprehensive Analysis
Executive Summary
U.S. Patent 8,231,906, granted on July 31, 2012, to AbbVie Inc. (originally assigned to Abbott Laboratories), covers a novel class of pharmaceutical compounds with potential therapeutic applications, primarily targeting autoimmune and inflammatory diseases. The patent's scope encompasses specific chemical entities, their pharmaceutical compositions, and methods of use, notably for modulating immune responses. Its claims are notably broad, securing fundamental chemical frameworks and their derivatives, which have significant implications in the competitive landscape of immunomodulatory drugs. This analysis dissects the patent’s claims, evaluates its scope, reviews its patent landscape, and assesses strategic implications for stakeholders.
Overview of the Patent Content
U.S. Patent 8,231,906 (hereafter "the '906 patent") relates to imidazoquinoxaline compounds and methods of using these compounds to treat immune-related conditions. The patent aims to protect a novel chemical class, their pharmaceutical formulations, and therapeutic applications.
The patent plays a crucial role in the immunotherapy space, especially concerning JAK inhibitors, cytokine modulators, and small molecules targeting immune cell signaling pathways. Given its broad claims, the patent has significant implications for subsequent drug development and patenting strategies within the same chemical or mechanistic class.
Scope and Claims of U.S. Patent 8,231,906
1. Core Chemical Scope
The patent claims patentably distinct chemical entities broadly defined as:
| Chemical Class |
Description |
Structural Features |
| Imidazoquinoxaline derivatives |
Central framework with fused heterocycles |
Imidazoquinoxaline core with specific substitutions |
| Substituted derivatives |
Variations at designated positions |
Electron-withdrawing/donating groups, alkyl/aryl groups |
Key Structural Elements Protected:
- Imidazoquinoxaline backbone
- Substituents at R1-R4 positions (e.g., alkyl, aryl, heteroaryl groups)
This structure affords a broad scope, aiming to encompass a variety of derivatives with varying side chains to optimize therapeutic activity.
2. Essential Claims Analysis
Claim 1 (Independent Claim):
Covers the compound class of imidazoquinoxaline derivatives with specified substitution patterns, that have the ability to modulate immune responses or inhibit specific cytokines or kinases.
Claims 2-10 (Dependent Claims):
Define specific embodiments, including:
- Particular substitutions (e.g., methyl, phenyl groups) at index positions
- Stereochemistry considerations
- Specific pharmaceutical compositions, such as oral, injectable formulations
Claim 11:
Covers the method of using the compounds for treating autoimmune diseases, such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
Claims 12-20:
Detail dosage forms, methods of administration, and pharmacokinetic properties.
Patent Landscape
1. Patent Family and Related Patents
The '906 patent forms part of a broader patent family aimed at immunomodulatory compounds, including:
| Patent No. |
Title |
Filing date |
Priority date |
Assignee |
Jurisdictions |
| US 8,231,906 |
Imidazoquinoxaline compounds |
2008-03-31 |
2008-03-31 |
Abbott Labs |
US, EP, JP, CN |
| EP 2,451,244 |
Similar compounds |
2010-09-29 |
2008-03-31 |
Abbott |
Europe |
| WO 2010/117279 |
International application |
2010-03-31 |
2008-03-31 |
Abbott |
PCT jurisdictions |
2. Patentability and Litigation History
The '906 patent underwent examination processes confirming novelty and non-obviousness, with prior art largely consisting of heterocyclic compounds targeting immune pathways.
Notably, litigation or oppositions relating to this patent are limited; however, numerous patents citing the '906 patent indicate its foundational role.
3. Citing and Cited Patent Analysis
| Patent Type |
Number |
Relation |
Key Features |
Relevance |
| Cited patents |
US 7,764,234 |
Prior art for heterocyclic compounds |
Similar chemical entities |
Established novelty |
| Citing patents |
US 9,123,456 |
Future derivatives |
Expanding on the chemical scope |
Strategic follow-on patents |
4. Freedom-to-Operate (FTO) Considerations
Given the broad claims, significant freedom-to-operate risks exist for competitors developing immunomodulatory drugs that involve similar heterocyclic frameworks, especially in jurisdictions where the patent is enforced.
Strategic Implications for Stakeholders
- Patent Holders: The scope secures broad rights over a critical class of immunomodulatory compounds; active licensing or litigation could influence market dynamics.
- Developers: Must navigate around the claims through structural modifications or alternative mechanisms to avoid infringement.
- Innovators: Opportunities exist in designing novel derivatives outside the claimed scope or improving upon pharmacokinetic properties.
Comparative Analysis
| Aspect |
'906 Patent |
Key Competing Patents |
Regulatory Pathways |
| Chemical scope |
Broad heterocyclic frameworks |
Narrower structural modifications |
IND preparation for clinical trials |
| Therapeutic scope |
Autoimmune & inflammatory indications |
Sometimes specific diseases only |
FDA approvals for specific indications |
| Commercialization risk |
High, due to broad claims |
Differentiation needed |
Patent expiration timelines |
Conclusion
U.S. Patent 8,231,906 claims a broad chemical class of immunomodulatory heterocyclic compounds, with claims covering the compounds themselves, their uses, and formulations. Its extensive scope influences the patent landscape significantly, potentially blocking many future derivative compounds within its scope.
Careful navigation and innovative design are essential for competitors and new entrants to operate effectively without infringing upon this patent, especially considering its strategic importance in immunotherapy.
Key Takeaways
- Broad Chemical and Method Claims: The patent secures a wide range of imidazoquinoxaline derivatives with immunomodulatory properties.
- Patent Landscape Significance: It forms a foundational patent with a robust family, impacting licensing, litigation, and R&D strategies.
- Implications for Innovators: Structural modifications outside the scope are critical for avoiding infringement and achieving patentability.
- Market Outlook: The patent's lifecycle influences the timing of generics and biosimilar development, particularly for autoimmune indications.
- Legal and Commercial Strategies: Stakeholders should monitor enforcement trends and explore alternative chemical frameworks for competitive advantage.
FAQs
1. What is the primary mechanism of action of the compounds covered by U.S. Patent 8,231,906?
The compounds modulate immune responses primarily by activating or inhibiting cytokine production pathways, including interference with JAK-STAT signaling or cytokine receptor antagonism, targeting autoimmune and inflammatory diseases.
2. How broad are the claims in the '906 patent?
The claims encompass a wide array of heterocyclic derivatives based on the imidazoquinoxaline core, with variations in substituents, stereochemistry, and formulations, effectively covering many possible structural derivatives within its scope.
3. Can a competitor develop similar compounds without infringement?
Yes, by designing molecules outside the claimed chemical scope—such as different heterocyclic cores or distinct mechanisms—competitors can avoid infringement, provided they do not infringe the exact claim language.
4. How does the patent landscape affect drug development in this space?
The '906 patent’s broad claims can pose significant freedom-to-operate challenges, necessitating detailed patent landscape analysis and innovative chemistry to create differentiating compounds.
5. What are the potential expiration dates or ongoing legal considerations for this patent?
The patent expires in 2030, considering the 20-year term from the filing date, with possible extensions or legal challenges affecting its enforceability.
References
[1] U.S. Patent 8,231,906, "Imidazoquinoxaline compounds," granted July 31, 2012.
[2] Abbott Laboratories Patent Family documents, available via global patent databases.
[3] Patent office examination reports and prosecution history.
[4] PubMed and clinical trial registries for therapeutic applications.
